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Abstract. Diabetes type 2 is a disease caused by a metabolic disorder. One of treatment of type 2 diabetes 
mellitus is focused on incretin hormone. Glucagon like peptide – 1 (GLP-1) is a insulintropic agent and plays a 
role in regulation of blood glucose. GLP-1 interacts with GLP-1R so the blood sugar level increases. DPP – IV is 
inhibitor are important biological target related for the treatmen of type 2 diabetes mellitus. DPP-IV inhibitor 
from drug synthetic have some side effect therefore develop natural DPP-IV inhibitor by in silico approaches. 
This research is study molecular interaction between DPP – IV inhibitor drug synthetic on the market was 
sitagliptin, vildagliptin, saxagliptin, anagliptin and alogliptin with compare bioactive ligan from Boesenbergia 
pandurata Roxb such as alipinetin, pinocembrin, pinostrobin, cardamonin, panduratin. The metodology used in 
the research is molecular docking using docking software. The results showed that DPP – IV inhibitor with 
vildagliptin had the best binding energy 15.49 Kcal/mol and torsional energy 19.69. Based on the analysis of 
docking in silico DPP-IV inhibitors with active compound Boesenbergia pandurata Roxb has binding energy 
2.39 Kcal/mol and torsional energy 5.5 and can be used as an antidiabetic drug candidate. 
Keywords : In Silico, Dipeptidyl peptidase IV, Beosenbergia pandurata Roxb, GLP-1, Diabetes mellitus, 
molecular docking. 
1.  Introduction  
Diabetes Mellitus is a disease caused by a metabolic disorders with a marked increase blood glucose 
levels. The global prevalence of diabetes in adults has increased over the past few decades (1). The 
prevalence of diabetes in the worldwide for all age groups is estimated to be 2.8% in 2000 and 4.4% in 
2030. The number of diabetics is predicted to increase from 171 million people in 2000 to 366 million 
people in 2030. Diabetics on cities in developing countries is predicted to double between 2000 and 
2030 (2). Diabetes mellitus classified in two general categories, type 1 diabetes mellitus characterized 
is due to autoimmune β-cell destruction, usually leading to absolute insulin deficiency. Type 2 
diabetes mellitus is due to loss of β-cell insulin secretion frequently on the background of insulin 
resistance (3). 
For the treatment of diabetes based on drugs available on the market such as insulin, secretagogues 
groups (such as sulfonylureas and incretins), and hypoglycemia groups (such as biguanides, 
thiazolidinediones) and drug combinations in different groups. These drugs are effective but can cause 
side effects such as heart complications, bone density loss, weight gain, digestive problems and 
urinary tract infections, therefore the development and challenges the search for new drugs diabetes 
mellitus is continuously carried out (4).  
Recently the treatment of type 2 diabetes mellitus has focused on incretin hormone. Glucagon like 
peptide-1 (GLP-1) and glucose dependent insulinotropic polypeptide (GIP) are the main incretin 
hormones secreted by intestinal cells. GLP-1 plays a role in the regulation of blood glucose levels 
because of their biological actions, such as stimulating the secretion of insulin, increasing β-cells 
mass, inhibiting the secretion of glucagon, reducing the rate gastric emptying levels and inducing 
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satiety. However, GLP-1 is rapidly metabolized by enzyme called dipeptidyl peptidase IV (DPP-IV) 
into inactive forms. Therefore the GLP-1 has a short half-life of about 1-2 min. DPP-IV inhibitors 
maintain the level of endogenous active GLP-1 levels and prolongs its half life (5).  
Dipeptidyl Peptidase IV (DPP-IV) inhibitor is a new treatment for type 2 diabetes mellitus. 
Inhibition of DPP-IV can increase levels of active GLP-1. GLP-1 can increase insulin secretion and 
reduce glucagon secretion, by reducing glucose levels in blood. Synthetic DPP-IV inhibitors show 
several side effects. Herbal medicines are alternative medicines over synthetic drugs which can relieve 
patients. Based on research have been carried all over the world related to the efficacy of herbs 
treatment of type 2 diabetes mellitus. Oral treatment of type 2 diabetes mellitus from herbal medicines 
is preferred to be prescribed because plant products have a lower toxicity than conventional medicines, 
low side effects and low cost (6).  
Boesenbergia pandurata Roxb is an Indonesian traditional medicinal plant that can be used to treat 
various diseases, one of which is antioxidants. This study aims to examine the antidiabetic of 
Boesenbergia pandurata Roxb which has not been tested especially in DPP-IV inhibitor activity (7). In 
this research we are in silico methods like molecular docking used to discover the ability of the natural 
from Boesenbergia Pandurata Roxb as treatment diabetes mellitus type 2. 
2.  Materials and Method  
2.1.  Protein and Ligan Structure 
The 3-D crystal structure of the protein DPP-IV inhibitor (PDB: ID 3WQH) was retrieved from 
protein data bank (PDB) with situs www.rcsb.org/pdb. The 3-D structure ligan Sitagliptin, 
Vildagliptin, Saxagliptin, Anagliptin, Alogliptin and molecule in Boesenbergia pandurata Roxb 
Alpinetin, Pinostrobin, Cardamonin, Pinocembrin, Panduratin were download from PubChem 
Compound Section of National Center for Biotechnology Information (NCBI) with situs 
https://pubchem.ncbi.nlm.nih.gov/. 
2.2.  Molecular Docking 
The docking protocol used in this study consisted of the following steps:  
1. Preparation of the ligands (construction of 3-D structures, setting the protonation state 
according with atomic charges employing semi-empirical method namely AM1 with 
hyperchem software). The ligand used consists of Sitagliptin, Vildagliptin, Saxagliptin, 
Anagliptin, Alogliptin and active compound Boesenbergia pandurata Roxb.  
2. Preparation of the macromolecule (The 3-D structure of the DPP-IV protein interaction with 
Anagliptin was downloaded from the protein data bank which PDB ID is 3WQH (8).  
3. The ligand and macromolecule structural is carried out by docking calculations using the 
Autodock Tools 1.5.6  software (9).  
4. Addition of  hydrogen atoms based on grid parameters for determine coordinate. What will be 
calculated are the pairs of energy potential and hydrogen bonds. Protonation of the main 
residues setting in the active site and running using Autogrid. 
5. Analyzing AutoDock results and Reading the Docking log. Procedure klik Analyze next 
docking next open. Analyze conformations next Load by convention these results files have 
the extension “.dlg” 
6. Analyzing AutoDock results and Visualizing Docked Conformations. The best docking results 
can be considered as the lowest energy conformation or can be selected based on RMS 
deviations from the reference structure. Autodock also breaks the total energy into vander 
waals energy and electrostatic energy for each atom. 
7. Analysis of AutoDock results and clustering conformation. To see the convergence of docking 
results, it can be seen from clustering. Docking convergence reflects into search. One result of 
docking is torsion of energy. The greater the torsion needed by the ligand, the greater the 
number of evaluations needed in the docking process. 
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3.  Results and Discussion  
The 2D structure of ligands (Alogliptin, Sitagliptin, Anagliptin, Vildagliptin, Saxagliptin) drug 
contain DPP-IV inhibitor is available in market and family bioactive compounds of flavonoid such as 
(Alpinetin, Pinostrobin, Cardamonin, Pinocembrin, Panduratin) found in Boesenbergia Pandurata 
Roxb can be shows in figure 1. 
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Figure 1. 2-D structure ligand (A) Alogliptin, (B) Sitagliptin, (C) Vildagliptin, (D) Anagliptin, (E) 
Saxagliptin, (F) Alpinetin, (G) Pinostrobin, (H) Pinocembrin, (I) Cardamonin, (J) Panduratin 
 
DPP-IV structure complex with anagliptin consisted of two independent protein molecules 
asymmetric bound in one anagliptin molecule. Three interaction substrates anagliptin with DPP-IV 
can be shows in figure 2 (1) The first site was S1 substitution which the cyano group had a dipole 
bond. The distance between the cyano carbon atoms and Oγ with the catalytic residue of Ser630 was 
2.8 Å and the distance between the cyano nitrogen atoms and Oᶯ with catalytic residues of Tyr547 is 
3.2 Å. (2) The second site was S2 substitution which the secondary amine form double salt bridges 
with a distance of 3.0 and 3.3 Å between the nitrogen atom of the secondary amine and each Oɛ of 
Glu205 and Glu206. (3) The third site was the substitution of S2 extensive which carbonyl group 
bound to the pyrazolopyrimidine ring formed a hydrogen bond with Nᶯ from Arg358 and the 
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Figure 2. Interaction of anagliptin in the active site of DPP-IV 
3.1.  Molecular docking  
 
Inhibitor DPP-IV activity was evaluated  by in silico study. Ligand used such as sitagliptin, 
vildagliptin, saxagliptin, anagliptin, alogliptin and active compound from Boesenbergia Pandurata 
Roxb such as alpinetin, pinostrobin, cardamonin, pinocembrin, panduratin  were docked with DPP-IV 
as protein and the results can be seen in table 1.  
Docking results show that vildagliptin and anagliptin have greater energy binding is 15.49 and 
10.11 Kcal/mol among other ligand (saxagliptin, alogliptin, sitagliptin) compounds. Which the active 
ligand compounds Boesenbergia Pandurata Roxb panduratin and cardamonin have a greater binding 
energy is 2.39 and 1.79 Kcal/mol compared to other ligand compounds. The differences in each 












Internal Energy Torsional 
Energy 
Vildagliptin 15.49 -4.19 -0.99 19.69 
Anagliptin 10.11 -1.22 -0.36 11.34 
Alogliptin 1 -0.27 -2.16 2.39 
Sitagliptin 1.6 -0.19 -2.94 1.79 
Saxagliptin 0.99 -0.21 -2.09 1.19 
Panduratin 2.39 0.0 -3.35 5.5 
Cardamonin  1.79 0.0 -1.35 5.22 
Alpinetin 0.89 0.0 -0.46 5.23 
Pinostrobin 0.89 0.0 -1.1 5.07 
Pinocembrin  0.89 0.0 -1.01 5.02 
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Boesenbergia pandurata Roxb is one of Zingiberaceae family, herbal plants contain saponin and 
flavonoid compounds such as pinostrobin, pinocembrin, alpinetin, cardamonin, and panduratin. Five 
active compound Boesenbergia pandurata Roxb which can be obtained from extraction and 
purification methods. All of them are classified into secondary metabolite groups and can be used to 
cure diseases (7). 
Herbal medicines are alternative medicines besides synthetic drugs that can relieve patients in the 
treatment of type 2 diabetes mellitus. The use of herbal medicines have minor side effects when given 
in large doses (6). 
 
4.  Conclusion  
Based on research conducted from five ligands (Alogliptin, Sitagliptin, Anagliptin, Vildagliptin, 
Saxagliptin) drugs containing DPP-IV inhibitors are available on the market. The best binding energy 
is vildagliptin 15.49 and torsional energy 19.69 compared to five ligands active compounds 
Boesenbergia Pandurata Roxb such as (Alpinetin, Pinostrobin, Cardamonin, Pinocembrin, Panduratin). 
The best results is Panduratin which has binding energy of 2.39 and torsional energy 5.5 suggested is 
good prospects for the treatment of type 2 diabetes mellitus. Therefore, further research and studies are 
needed in vitro and clinics. 
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